---
accession : E-GEOD-10086
platform  : A-AFFY-37
pathway   : MAPK
cells     : SK-MEL-1,5,19,28 melanoma cell lines
treatment : PD0325901
effect    : inhibiting
hours     : 8

control   :
    - GSE10086GSM254947
    - GSE10086GSM254949
    - GSE10086GSM254951
    - GSE10086GSM254953
treatment :
    - GSE10086GSM254948
    - GSE10086GSM254950
    - GSE10086GSM254952
    - GSE10086GSM254954

---
accession : E-GEOD-10086
platform  : A-AFFY-37
pathway   : MAPK
cells     : SkBr3, MDA-MB-468 cell lines (mammary gland/breast; derived from pleural effusion)
treatment : PD0325901
effect    : inhibiting
hours     : 8

control   :
    - GSE10086GSM254931
    - GSE10086GSM254939
treatment :
    - GSE10086GSM254932
    - GSE10086GSM254940

---
accession : E-GEOD-10086
platform  : A-AFFY-37
pathway   : MAPK
cells     : Colo-205, HT-29 colorectal cancer cell lines
treatment : PD0325901
effect    : inhibiting
hours     : 8

control   :
    - GSE10086GSM254941
    - GSE10086GSM254943
treatment :
    - GSE10086GSM254942
    - GSE10086GSM254944

---
accession : E-GEOD-10086
platform  : A-AFFY-37
pathway   : MAPK
cells     : BT474 xenograft
treatment : PD0325901
effect    : inhibiting
hours     : 8

control   :
    - GSE10086GSM254955
    - GSE10086GSM254956
treatment :
    - GSE10086GSM254959
    - GSE10086GSM254960

---
accession : E-GEOD-10086
platform  : A-AFFY-37
pathway   : MAPK
cells     : SkMel-28 xenograft
treatment : PD0325901
effect    : inhibiting
hours     : 8

control   :
    - GSE10086GSM254957
    - GSE10086GSM254958
treatment :
    - GSE10086GSM254961
    - GSE10086GSM254962
...
